New Staff Spotlight: Ehud Goldin, PhD

Posted by Iain Inkster on June 07, 2013 | Degradation of A2E

Dr. Ehud Goldin has recently joined SENS Research Foundation as head of the Research Center’s A2E degradation project. His work will be to enable the lysosomes of retinal pigment epithelial cells to degrade A2E...

CR in Nonhuman Primates: A Muddle for Monkeys, Men, and Mimetics

Posted by Michael Rae on May 06, 2013 | Chief Science Officer's Team

Two quarter-century long studies on the effects of Calorie restriction in nonhuman primates have come to opposing results. What do these results mean for the human translatability of CR, and the future of therapies to prevent and cure the diseases and disabilities of aging?

Cell Reprogramming Leaps Ahead: First Transplant of Primate Induced Pluripotent Cell-Derived Neurons into Donor Brain

Posted by Michael Rae on April 17, 2013 | Chief Science Officer's Team

"Reprogramming" of adult differentiated cells into pluripotent stem cells is an exciting method in biology that holds enormous promise for rejuvenation biotechnology. Now, for the first time, Dr. Su-Chun Zhang and coworkers at the University of Wisconsin-Madison have successfully generated neurons from reprogrammed nonhuman primate cells, transplanted them back into the same animal's brain, and seen them successfully and cleanly integrate into the local tissue.

SRF-Funded PhD Candidate Publishes

Posted by Daniel Kimbel on March 15, 2013 | Extra-mural Research

David Brindley, a SENS Research Foundation-funded PhD candidate at the University of Oxford, is the lead author on a new publication in the journal BioProcess International discussing the automation of cell therapy biomanufacturing.

SRF's Research Advisory Board Welcomes Dr. George Church

Posted by Ben Zealley on March 07, 2013 | Research Advisory Board

SENS Research Foundation is delighted to welcome Dr. George Church, Professor of Genetics at Harvard Medical School, to our Research Advisory Board. Our RAB plays a key role in our mission to change the way the world researches and treats age-related disease. By applying expertise from multiple relevant areas, the Board assures that efforts and resources are directed along the most promising avenues.

Project: Break Aging Arteries Free

Posted by Michael Rae on March 05, 2013 | GlycoSENS

SENS Research Foundation has established a new research center at Cambridge University and a collaboration with scientists at Yale University. The mission: develop new therapies to repair a critical form of molecular damage that drives the slow stiffening of the arteries with age. Such rejuvenation biotechnologies could prevent such deadly and disabling diseases of aging as stroke and kidney disease.

"Accelerated Aging:" Inspiration Beyond Equivocation

Posted by Michael Rae on September 26, 2012 | Chief Science Officer's Team

The preliminary results of a clinical trial for a disease of "premature aging" - Hutchinson-Gilford Progeria Syndrome (HGPS) - are hopeful and inspiring. However, they cannot directly inform the development of rejuvenation biotechnologies; although the symptoms of HGPS are similar to those observed in aging, there is no evidence to suggest that the underlying mechanism is pathologically significant in those not afflicted with the disease.

Biomek 2000

Posted by Reto Hoehener on September 24, 2012 | Laboratory Automation

Reto Hoehner, a SENS Research Foundation volunteer, discusses his work in getting a second-hand Biomek 2000 - a high-throughput PCR automation robot - up and running at our Research Center in Mountain View, and goes on to discuss some use cases and limitations of the hardware.

ShARM: The Miracle of the Loaves and Fishes comes to Aging Research

Posted by Michael Rae on August 17, 2012 | Chief Science Officer's Team

Aging laboratory rodents are the foundation of our ability to study the degenerative aging process, and develop the rejuvenation biotechnologies that will arrest and reverse it. They're also expensive, logistically intensive, and in short supply. A new UK initiative has been establish to greatly expand what we can learn from the aging animals in our collective care, and to get a fuller picture of aging and its deceleration and reversal than has hitherto been possible.

Tale of Telomerase: Lessons and Limits in a Late-Life Launch

Posted by Michael Rae on May 21, 2012 | Chief Science Officer's Team

Recent studies show the potential - and the limits - of inducing telomerase expression in aging mice. We place these results in context and explore their implications for new treatments targeting age-related degeneration in humans, particularly examining how telomerase activity relates to the development of cancer.

Toward Regenerative Medicine Against Atherosclerosis

Posted by Michael Rae on May 04, 2012 | Chief Science Officer's Team

SENS Foundation-funded research shows that expression of a modified microbial enzyme protects human cells against 7-ketocholesterol toxicity, advancing research toward remediation of the foam cell and rejuvenation of the atherosclerotic artery.

By Looped Hook and Targeting Crook: Potential Game-Changer for "Allotopic" Mitochondrial RNA

Posted by Michael Rae on March 15, 2012 | Chief Science Officer's Team

UCLA Researchers have exploited a recently-discovered mammalian system for the mitochondrial import of nuclear-encoded RNA to import, express, and demonstrate functional protein translation from engineered mRNA and tRNA constructs. They used this system, with modifications for mitochondrial targeting and orthotopic translation, to rescue respiration in human mitochondriopathy cells. While further characterization and extension is clearly needed, this approach appears offer great promise for the correction of age-related mitochondrial DNA mutations.